Pomerantz Law Firm Investigates Potential Fraud at Capricor Therapeutics for Investors

Investigation into Capricor Therapeutics

On August 6, 2025, Pomerantz LLP, a renowned law firm with a legacy in class action litigation, announced its investigation on behalf of investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). The inquiry is centered around allegations of securities fraud and unlawful business practices concerning the company and its executives.

Background of the Investigation

Capricor Therapeutics is a biotechnology company currently working on innovative treatments, including deramiocel, aimed at combating Duchenne muscular dystrophy (DMD) cardiomyopathy. On May 5, 2025, Capricor announced that it had completed a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for deramiocel. According to the firm, the FDA confirmed it would hold an advisory committee meeting related to this application.

However, shortly thereafter, significant market movements occurred. On May 6, 2025, following the announcement, Capricor's stock experienced a sharp decline, dropping $3.00 or 29.13%, concluding the day at $7.30 per share. The situation worsened when, on June 20, 2025, STAT revealed that the FDA had canceled the anticipated advisory committee meeting due to safety and efficacy concerns regarding deramiocel. This further setback led to another plummet in Capricor's stock, which fell by $3.68 or 30.82%, closing at $8.26 per share.

The Role of Pomerantz LLP

Pomerantz LLP has been a significant player in corporate and securities class litigation for over 85 years. Led by their commitment to justice and advocacy for victims of fraud and misconduct, the firm has established a strong reputation in this field. Founded by Abraham L. Pomerantz, dubbed the dean of the class action bar, they continue his legacy fighting for shareholders' rights and seeking reparations for corporate misdeeds.

Investors with concerns about their potential losses are encouraged to contact Danielle Peyton at Pomerantz LLP via phone or email. The firm aims to provide support and possibly join a larger class action to hold Capricor accountable if sufficient evidence of wrongdoing is found.

Despite the challenges Capricor faces, including scrutiny by regulators and investors alike, the pathway to accountability is rooted firmly in shareholder activism and legal recourse—hallmarks of Pomerantz's approach. The firm’s proven track record of successful outcomes in similar cases positions it well to address these complex issues. Investors are thus empowered to stand up against corporate malpractice with the help of seasoned legal professionals.

Conclusion

Pomerantz LLP’s investigation into Capricor Therapeutics highlights the complexities surrounding corporate transparency, investor protection, and ethical conduct. As the situation evolves, the actions taken by both the shareholders and the law firm will undoubtedly influence the broader discussion about accountability in the biotech sector. Stakeholders are urged to stay informed and consider reaching out to Pomerantz LLP for further assistance as this case progresses.